Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2016, Article ID 5383797, 8 pages
http://dx.doi.org/10.1155/2016/5383797
Clinical Study

Effect of Ranirestat on Sensory and Motor Nerve Function in Japanese Patients with Diabetic Polyneuropathy: A Randomized Double-Blind Placebo-Controlled Study

1NTT-EAST Tohoku Hospital, 2-29-1 Yamato-machi, Wakabayashi-ku, Sendai, Miyagi 984-8560, Japan
2Department of Neurology, Kobe City Medical Center General Hospital, 4-6 Minatojima-Nakamachi, Chuo-ku, Kobe, Hyogo 650-0046, Japan
3Division of Neurology, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan
4Sumitomo Dainippon Pharma, Co., Ltd., 6-8 Doshomachi 2-chome, Chuo-ku, Osaka 541-0045, Japan

Received 31 August 2015; Revised 2 November 2015; Accepted 17 December 2015

Academic Editor: Rodica Pop-Busui

Copyright © 2016 Jo Satoh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Yagihashi, H. Mizukami, and K. Sugimoto, “Mechanism of diabetic neuropathy: where are we now and where to go?” Journal of Diabetes Investigation, vol. 2, no. 1, pp. 18–32, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. D. A. Greene, J. C. Arezzo, and M. B. Brown, “Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy,” Neurology, vol. 53, no. 3, pp. 580–591, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. V. Bril, R. A. Buchanan, and The AS-3201 Study Group, “Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy,” Diabetes Care, vol. 27, no. 10, pp. 2369–2375, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. V. Bril and R. A. Buchanan, “Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy,” Diabetes Care, vol. 29, no. 1, pp. 68–72, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. V. Bril and B. A. Perkins, “Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy,” Diabetes Care, vol. 25, no. 11, pp. 2048–2052, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. V. Bril, S. Tomioka, R. A. Buchanan, B. A. Perkins, and The mTCNS Study Group, “Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy,” Diabetic Medicine, vol. 26, no. 3, pp. 240–246, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Satoh, N. Kohara, and C. Hamada, “Assessment of the reliability of a Japanese version of the modified toronto clinical neuropathy score in Japanese patients with diabetic sensorimotor polyneuropathy,” Journal of the Japan Diabetes Society, vol. 56, no. 12, pp. 932–937, 2013. View at Google Scholar · View at Scopus
  8. A. Kashiwagi, M. Kasuga, E. Araki et al., “International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values,” Diabetology International, vol. 3, no. 1, pp. 8–10, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Kashiwagi, M. Kasuga, E. Araki et al., “International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values,” Journal of Diabetes Investigation, vol. 3, no. 1, pp. 39–40, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. V. Bril, R. Ellison, M. Ngo et al., “Electrophysiological monitoring in clinical trials,” Muscle and Nerve, vol. 21, no. 11, pp. 1368–1373, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. Diabetes Control and Complications Trial Research Group, “Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial,” Annals of Neurology, vol. 38, no. 6, pp. 869–880, 1995. View at Google Scholar
  12. N. Hotta, Y. Akanuma, R. Kawamori et al., “Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative aldose reductase inhibitor-diabetes complications trial,” Diabetes Care, vol. 29, no. 7, pp. 1538–1544, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. V. Bril, T. Hirose, S. Tomioka, and R. Buchanan, “Ranirestat for the management of diabetic sensorimotor polyneuropathy,” Diabetes Care, vol. 32, no. 7, pp. 1256–1260, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. C. A. Abbott, A. L. Carrington, H. Ashe et al., “The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort,” Diabetic Medicine, vol. 19, no. 5, pp. 377–384, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Polydefkis, J. Arezzo, M. Nash et al., “Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy,” Journal of the Peripheral Nervous System, vol. 20, no. 4, pp. 363–371, 2015. View at Publisher · View at Google Scholar
  16. A. I. Vinik, V. Bril, P. Kempler et al., “Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C β-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial,” Clinical Therapeutics, vol. 27, no. 8, pp. 1164–1180, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Ziegler, A. Ametov, A. Barinov et al., “Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy,” Diabetes Care, vol. 29, no. 11, pp. 2365–2370, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Laudadio and A. A. F. Sima, “Progression rates of diabetic neuropathy in placebo patients in an 18-month clinical trial,” Journal of Diabetes and Its Complications, vol. 12, no. 3, pp. 121–127, 1988. View at Publisher · View at Google Scholar